Corticotropin-releasing hormone receptor expression and functional signaling in murine gonadotrope-like cells

Audrey F Seasholtz¹,², Miina Öhman³, Amale Wardani¹ and Robert C Thompson¹,³

¹Molecular and Behavioral Neuroscience Institute ²Department of Biological Chemistry and ³Department of Psychiatry, University of Michigan, 109 Zina Pitcher Place, BSBB Room 5015, Ann Arbor, Michigan 48109, USA

(Correspondence should be addressed to A F Seasholtz; Email: aseashol@umich.edu)

(M Öhman is now at Department of Internal Medicine, Cardiology, University of Michigan, Ann Arbor, Michigan, USA)

Abstract

Corticotropin-releasing hormone (CRH) is a key regulator of the mammalian stress response, mediating a wide variety of stress-associated behaviors including stress-induced inhibition of reproductive function. To investigate the potential direct action of CRH on pituitary gonadotrope function, we examined CRH receptor expression and second messenger signaling in αT3-1 cells, a murine gonadotrope-like cell line. Reverse transcriptase PCR (RT-PCR) studies demonstrated that αT3-1 cells express mRNA for the two CRH receptor subtypes, CRHR1 and CRHR2, with CRHR2α as the predominant CRHR2 isoform. Stimulation of the cells with CRH or urocortin (UCN) resulted in rapid, transient increases in the intracellular levels of cAMP that were completely blocked by the addition of α-helical CRH 9-41 or astressin, non-selective CRH receptor antagonists. Stimulation of the cells with CRHR2-specific ligands, urocortin 2 (UCN2) or urocortin 3 (UCN3), resulted in rapid increases in intracellular cAMP levels to 50–60% of the levels observed with UCN. Treatment with a selective CRHR2 antagonist, antisauvagine, completely blocked UCN3-mediated increases in cAMP and significantly reduced, but did not completely block UCN-mediated increases in cAMP, demonstrating that both CRHR1 and CRHR2 are functionally active in these gonadotrope-like cells. Finally, UCN treatment significantly increased the transcriptional activity of the glycoprotein hormone α-subunit promoter as assessed by α-luciferase transfection assays. Together, these results demonstrate the functional signaling of CRH receptors in αT3-1 cells, suggesting that CRH may also modulate pituitary gonadotrope function in vivo.


Introduction

Corticotropin-releasing hormone (CRH) is a key regulator of the endocrine, behavioral, and autonomic components of the mammalian stress response. Within the endocrine hypothalamic–pituitary–adrenal axis, this 41-amino acid peptide is the key mediator of ACTH secretion. Hypothalamic CRH is released in response to stressful stimuli and carried to the anterior pituitary where it activates CRH receptors on anterior pituitary corticotropes, resulting in increased ACTH synthesis and secretion. ACTH acts on the adrenal cortex to increase glucocorticoid release; glucocorticoids then mediate many of the metabolic changes required to respond to the stressor. CRH is also expressed in many other sites in the central nervous system (CNS) where it is thought to act as a neurotransmitter to mediate changes in a wide variety of stress-associated behaviors. For example, CRH has been implicated in stress-induced alterations in anxiety-like behavior, feeding behavior, and locomotor activity (Dunn & Berridge 1990, Owens & Nemeroff 1991).

CRH has also been shown to play an important role in stress-induced inhibition of reproductive function. The i.c.v. injection of CRH suppresses the activity of the hypothalamic–pituitary–gonadal (HPG) axis in rats, resulting in decreased release of GnRH1 and LH (LHB; reviewed in Rivest & Rivier (1995)). Similarly, the repression of pulsatile LHB secretion by restraint stress, lipopolysaccharide, insulin-induced hypoglycemia, or fasting can be reversed by the icv injection of CRH receptor antagonists (Maeda et al. 1994, Li et al. 2005, 2006), suggesting that CRH receptor ligands mediate inhibitory effects of stress on the HPG axis via central pathways (reviewed in Rivest & Rivier (1995)). While studies suggest that systemic administration of CRH does not alter LHB secretion in rats (Rivier & Vale 1984), CRH treatment of primary rat pituitary cultures decreased basal LHB secretion (Blank et al. 1986). Numerous other hypothalamic peptides have also been shown to modulate gonadotropin levels by acting at the pituitary (reviewed in Evans (1999)). Thus, CRH and other members of the CRH family of peptides, urocortin (UCN), urocortin 2 (UCN2), and urocortin 3 (UCN3), may participate in the stress-mediated regulation of reproduction via multiple mechanisms and sites of action.
CRH and the urocortins mediate their effects via two distinct CRH receptors: CRHR1 and CRHR2 (reviewed in Dautzenberg & Hauger (2002), Grammatopoulos & Chrousos (2002), Bale & Vale (2004) and Hillhouse & Grammatopoulos (2006)). The receptors are ~70% identical at the amino acid level and are both members of the class B subfamily of seven transmembrane domain G-protein-coupled receptors. In most cell types, the activation of CRHR1 or CRHR2 by CRH or urocortins results in the activation of the G\textsubscript{s}-adenyl cyclase pathway and increased cAMP levels; however, recent evidence has demonstrated that in some tissues and cell types both CRH receptors can couple to other G-proteins including Gq, G\textsubscript{i}, and G\textsubscript{o}, resulting in the activation of various kinases including PKC, MAPK, and Akt1 (reviewed in Grammatopoulos & Chrousos (2002) and Hillhouse & Grammatopoulos (2006)). CRHR1 and CRHR2 differ in their pharmacological properties (reviewed in Dautzenberg & Hauger (2002), Grammatopoulos & Chrousos (2002), Bale & Vale (2004) and Hillhouse & Grammatopoulos (2006)). CRHR1 has very high affinity for both CRH and UCN (Vaughan et al. 1995). By contrast, CRHR2 has a significantly higher affinity (20- to 40-fold) for UCN than for CRH (Vaughan et al. 1995); UCN2 and UCN3 are relatively selective for CRHR2, and have been suggested to be CRHR2-specific ligands (Hsu & Hsueh 2001, Lewis et al. 2001, Reyes et al. 1995). CRHR1 has been detected in numerous sites in the brain (i.e., cerebellum, cerebral cortex, amygdala, various limbic, and sensory nuclei), the intermediate lobe of the pituitary, and a subset of corticotropes in the anterior lobe of the rat pituitary (Potter et al. 1994, Van Pett et al. 2000). Recent studies from our laboratory have demonstrated Crhr1 mRNA not only in a subset of corticotropes but also in a subset of lactotropes and gonadotropes in murine anterior pituitary (Westphal et al. 2009). CRHR2 has been isolated in two alternatively spliced forms in the rodent (CRHR2\textsubscript{a} and CRHR2\textsubscript{b} which utilize alternative amino termini) and exhibits an mRNA expression profile that is distinct from that of CRHR1 (Chalmers et al. 1995, Lovenberg et al. 1995b). CRHR2\textsubscript{a} is expressed primarily in brain (Chalmers et al. 1995, Lovenberg et al. 1995a), while CRHR2\textsubscript{b} is found largely in the periphery, but is also detected in the choroid plexus and cerebral arterialies (Chalmers et al. 1995, Lovenberg et al. 1995a). Within the pituitary, CRHR2 is expressed predominantly in the posterior lobe; however, a very low but detectable level of Crhr2 mRNA is also detected in the anterior lobe by in situ hybridization (Van Pett et al. 2000, Kageyama et al. 2003). Consistent with the potential expression of CRHR2 in anterior pituitary, Kageyama and colleagues recently demonstrated CRHR2\textsubscript{a} mRNA in rat anterior pituitary and Crhr2 mRNA in rat gonadotropes (Kageyama et al. 2003). These results suggest that both CRHR1 and CRHR2 may bind CRH and urocortins not only in the CNS but also in the pituitary to modulate stress-related functions.

To investigate the potential action of CRH specifically on pituitary gonadotrope function, we examined the CRH receptor expression and functional signaling in \(\alpha\)T3-1 cells, a murine gonadotrope precursor cell line. These cells were originally derived by targeted oncogenesis in transgenic mice (Windle et al. 1990) and they express GNRH1 receptors and the \(\alpha\)-subunit of the glycoprotein hormone, but not LHB or FSHB. They exhibit a number of characteristics equivalent to gonadotropes in primary pituitary cultures, demonstrating the utility of these cells as a model system for the study of gonadotrope function (Horn et al. 1991).

### Materials and Methods

#### Cell culture

\(\alpha\)T3-1 cells were kindly provided by Dr Pamela Mellon (University of California, San Diego; Windle et al. 1990). They were maintained in DMEM and preincubated for 45–60 min in DMEM containing 1 mM isobutylmethyl-xanthine (IBMX; Sigma) to inhibit cAMP phosphodiesterase activity. Preincubation media were removed and DMEM (1 ml) containing 1 mM IBMX and various concentrations of human/rat CRH, rat UCN, mouse UCN2, mouse UCN3, \(\alpha\)-helical CRH (9-41), astressin (AST; American Peptide Company, Sunnyvale, CA, USA), or antisauvagine (Bachem, Torrance, CA, USA) were added. The cells were incubated at room temperature for the indicated lengths of time before the removal of stimulation media. Then the cells were immediately lysed and intracellular cAMP levels were determined. The cyclic AMP (\(^{3}H\)) assay system (Amersham Biosciences) was used for the time-course, dose–response profiles with CRH and UCN, and \(\alpha\)-helical CRH 9-41 and AST antagonist studies. In this assay, the cells were lysed and incubated for 16–24 h at \(-20^\circ\text{C}\) with 95% ethanol/20 mM HCl (1 ml/well). Cell lysates were then dried under vacuum, resuspended in 300 \(\mu\)l of 0·05 M Tris (pH 7·5), 4 mM EDTA, and cAMP levels were determined in 50 \(\mu\)l samples, according to the manufacturer’s protocol, using triplicate wells and duplicate assays for each time point or treatment value. Additional dose–response studies with UCN, UCN2, and UCN3 and antisauvagine antagonist studies were performed with the direct cAMP enzyme Immunoassay kit (catalog no. 901-066; Assay Designs Inc., Ann Arbor, MI, USA). After the removal of the stimulation media, the cells were lysed by 20-minute incubation in 1 ml of 0·1 M HCl. The cell lysates were centrifuged at 600 \(g\) at room temperature for 5 min and the supernatants were used directly in the assay (50 \(\mu\)l/well) or stored at \(-20^\circ\text{C}\).

---

*Journal of Endocrinology (2009) 200, 223–232*
As above, duplicate assays and duplicate or triplicate wells were used for each treatment condition. Each experiment was performed at least two times; dose profiles were repeated three to five times.

**RNA isolation and cDNA synthesis**

Total RNA was isolated from mouse brain, hypothalamus, heart, and αT3-1 cells using TRIzol reagent (Invitrogen). Five micrograms of RNA were used for random hexamer-primed first-strand cDNA synthesis (Novagen Inc, Madison, WI, USA). To control for genomic DNA contamination, cDNA synthesis was performed in the presence and absence of SuperScript II Reverse Transcriptase (Life Technologies, Inc.) for each of the RNA samples. The products of cDNA synthesis were purified using QIAquick PCR Purification kit (Qiagen Inc).

**RT-PCRs**

RT-PCR was performed in a final volume of 25 or 50 μl using 1–3 μl cDNA product, 200 μM deoxynucleotides, 10 mM primers, Taq buffer with MgCl2, and 1–25 U Taq DNA polymerase or platinum Taq DNA polymerase (Invitrogen Inc). Cycle conditions are described below. Based on the mouse CRHR1 genomic structure (Ensembl ENSMUST00000093925), the primers for mouse CRHR1 were designed to span at least one intron in the genomic sequence. The primer pair for CRHR1 (Fig. 1A) was as follows: forward primer, 5′-GGA-TCA-GCA-GTG-GAG-CCT-3′ and reverse primer, 5′-GTG-CCA-GTG-GAT-GAT-GTT-CCT-3′ (amplifying a 394 bp fragment from nucleotides 109 to 502 of mouse Crhr1 cDNA, GenBank accession no. X72305). PCR amplification conditions were 34 cycles of 94 °C for 30 s, 68 °C for 30 s, and 72 °C for 30 s.

The genomic organization and the sequence of mouse CRHR2 were recently published (Chen et al. 2005). Exons 1 and 2 are spliced to exon 4 to produce CRHR2β while exon 3 is spliced to exon 4 to produce CRHR2α. Our primers for PCR were designed to span at least one intron. For CRHR2α, the forward primer was 5′-CTC-CTG-CTG-GAC-GGC-AAC-T-3′ and the reverse primer was 5′-CTC-GAG-CAT-TGA-TGT-GAG-ATT-3′ (exons 3–5, amplifying a 243 bp fragment from nucleotides 158 to 400 of mouse Crhr2α cDNA, GenBank accession no. AY445512). For CRHR2β, the forward primer was 5′-GGG-CTA-AGA-GAG-CCG-GAC-ACT-CCT-TTC-GGA-3′ and the reverse primer was 5′-AGG-ATG-AGG-ATG-TGG-GAG-ATT-CAG-TGG-ATC-ACA-3′ (exons 1–7, amplifying a 631 bp fragment from nucleotides 40 to 670 of mouse CRHR2α cDNA, GenBank accession no. NM_009953). Both PCR amplifications included 30 cycles of 92 °C for 60 s, 66 °C for 90 s, and 72 °C for 90 s.

All PCR products were electrophoresed and visualized on an ethidium bromide-stained 1% agarose gel. The 1 kb plus DNA ladder (Fig. 1A) or 1 kb DNA ladder (Fig. 1B and C; Invitrogen) was used for DNA size standards.

**Transient transfections and reporter constructs**

Cultures of αT3-1 cells were plated onto 6-well plates (400 000 cells/well) in DMEM + 10% FCS + gentamicin (50 μg/ml). The cells were transfected 12–24 h later, using FuGENE (see the manufacturer's recommendations; Roche) with 1:75 μg luciferase reporter DNA and 0:25 μg RSV-βgal DNA per well. The α-subunit–luciferase construct was kindly provided by Dr Sally Camper (University of Michigan) and contains 480 bp of the mouse glycoprotein hormone α-subunit promoter (−480 to +43 bp) fused to the luciferase reporter gene (Brinkmeier et al. 1998). RSV-βgal was used to normalize for transfection efficiency. For all studies, 10 μM forskolin (Calbiochem, San Diego, CA, USA) or various concentrations of UCN peptides were applied at 40 h post-transfection. The cells were harvested 4 h later (44 h post-transfection) in cold 1× PBS, pelleted, and lysed in 100 μl lysis buffer (0:25 M Tris (pH 8.0), 0:1 M EDTA, 15 mM MgSO4, 1 mM DTT, and 1% Triton X-100) and incubated on ice for 10 min. lysates were centrifuged at 10 000 r.p.m. for 10 min at 4 °C and 5 μl of each supernatant were added to 100 μl of luciferase assay buffer (Cortright et al. 1997) and assayed for 30 s in a Turner 20/20 luminometer; β-galactosidase activity was assayed as described previously. Data are represented as fold induction over untreated vehicle control (untreated controls = 1:0). Experiments were performed in duplicate and each experiment was repeated at least three independent times. Fold inductions from three independent experiments were combined for the α-luciferase transfection data presented.

**Data analysis and statistical methods**

All data are presented as mean ± s.e.m. Statistical significance of the cAMP responses over time and in the presence of CRH receptor antagonists was determined by ANOVA with post hoc analysis using StatView (Abacus Concepts). Duplicate or triplicate wells were used for all cAMP assays and at least two to five independent assays were performed for each study. The EC50 values for CRH, UCN, UCN2, and UCN3 were determined by non-linear regression analyses using GraphPad Prism (version 3.0) software (GraphPad). Statistical analysis for the transient transfection studies was performed using a one-way ANOVA followed by multiple comparison post hoc analysis, where all selected groups were analyzed simultaneously. Analysis was performed using StatView and p values that reached 95% confidence levels are included in each figure legend.

**Results**

**Expression of CRH receptor mRNA in αT3-1 cells**

RT-PCR was utilized to characterize the expression of Crhr1 and Crhr2 mRNA in αT3-1 cells. cDNA synthesis reactions

---

[www.endocrinology-journals.org](http://www.endocrinology-journals.org)
Expression of CRHR1 and CRHR2α RNA in αT3-1 cells. RT-PCR was utilized to test for the expression of CRH receptor RNA in αT3-1 cells. (A) Utilizes primers specific for CRHR1 and (B) and (C) utilize primers specific for CRHR2α and CRHR2β respectively. The presence or absence of reverse transcriptase (RT) during cDNA synthesis is indicated by + or − signs. (A) An amplified product of 394 bp in hypothalamus and αT3-1 cDNA lanes (see arrow). Hy+ (hypothalamus, with RT), Hy− (hypothalamus, without RT), αT+ (αT3-1, with RT), αT− (αT3-1, without RT), W (water control). (B) An amplified product of 243 bp in αT3-1 (αT+) and brain (Br+) cDNA lanes (see arrow). These bands are consistent with the expression of CRHR2α in αT3-1 and total brain RNA samples. (C) Amplified products of 631 bp only in the brain (Br+) lane (see arrow). The absence of amplified product in the αT+ lane indicates that CRHR2β is not detectable in αT3-1 RNA. M represents 1 kb plus (Invitrogen) DNA ladder in (A) and 1 kb (Invitrogen) DNA ladder in (B) and (C).

Stimulation of cAMP production in αT3-1 cells by CRH and UCN

CRH receptors have been shown to couple to Gs in many tissues and cell lines, resulting in increased intracellular cAMP levels. To test the intracellular signaling of the CRH receptors in αT3-1 cells, the cells were treated with 200 nM CRH or UCN in the presence of 1 mM IBMX for various lengths of time and cAMP production was examined. UCN and CRH bind to both CRHR1 and CRHR2, although CRH binds to CRHR2 with a 14-fold lower affinity than CRHR1 (K_i = 13 and 0.95 nM respectively), while UCN binds to both CRHR1 and CRHR2 with very high affinity (K_i < 1.0 nM). As shown in Fig. 2, treatment of αT3-1 cells with CRH or UCN resulted in rapid increases in the intracellular cAMP levels. The CRH- and UCN-mediated increases in cAMP were maximal at 2–5 min and were significantly increased over the levels in vehicle-treated cells (dashed line). The increased cAMP levels were usually twofold to fourfold over basal levels, and maximal levels of cAMP did not significantly differ between CRH and UCN treatments within the experiments. Interestingly, the intracellular cAMP levels decreased rapidly from peak values even in the presence of 1 mM IBMX.

Dose-dependent stimulation of cAMP production in αT3-1 cells by CRH and UCN

Dose–response studies were performed using various concentrations of CRH or UCN in the presence of 1 mM IBMX. As time-course experiments had shown maximal
intracellular cAMP levels at 2–5 min after the addition of ligand, all treatments were for 3 min. As shown in Fig. 3, cAMP levels increased in αT3-1 cells in a dose-dependent fashion in response to CRH or UCN treatment. CRH and UCN were similar in potency and showed equivalent maximum cAMP levels across multiple experiments. The half-maximal stimulatory (EC50) concentrations of CRH and UCN were not significantly different with the values of 14.5 nM (G 5.9 (n Z 3)) and 21.2 nM (G 5.1 (n Z 7)) respectively.

Inhibition of CRH- and UCN-mediated increases in cAMP with non-selective CRH receptor antagonists

We used CRH receptor antagonists (α-helical CRH 9-41 and AST) that block both CRHR1 and CRHR2 (reviewed in Hauger et al. (2006)) to determine whether the CRH- and UCN-mediated increases in intracellular cAMP were specifically mediated by CRH receptors. The cells were pretreated for 1 h with 1 mM IBMX and fresh media were added that contained 100 nM CRH or UCN in the presence or absence of 10 μM α-helical CRH 9-41 (9-41, Fig. 4A) or 1 μM AST (Fig. 4B). Cells were also treated with vehicle or receptor antagonist alone. All treatments were for 3 min. α-Helical CRH 9-41 treatment alone showed a small but significant increase in the intracellular cAMP levels (Fig. 4A). CRH or UCN treatment alone also resulted in a significant increase in cAMP, while co-administration with α-helical CRH 9-41 reduced cAMP values to vehicle-treated levels. The α-helical CRH 9-41 results shown here are consistent with the previous studies that suggest that it is not a pure antagonist, demonstrating

**Figure 2** Time-dependent increases in intracellular cAMP levels in αT3-1 cells after treatment with CRH or UCN. The cells were treated with 200 nM CRH or UCN for 2, 5, 10, 20, and 40 min in the presence of 1 mM IBMX. cAMP assays were performed on cell lysates. The addition of CRH (□) or UCN (○) resulted in a rapid increase in intracellular cAMP levels when compared with vehicle treatment (dashed line). Points represent the average (± S.E.M.) for triplicate wells from a representative experiment.

**Figure 3** Dose-dependent increases in cAMP levels in αT3-1 cells following treatment by CRH (□) or UCN (△). Intracellular levels of cAMP are shown after the treatment of αT3-1 cells with various concentrations of CRH or UCN. Treatments were for 3 min. Points are the average (± S.E.M.) from duplicate assays on triplicate wells from a representative experiment. The maximal cAMP levels are not significantly different following CRH or UCN treatment and the EC50 values are also not significantly different.

**Figure 4** Inhibition of CRH- or UCN-mediated stimulation of cAMP levels by CRH receptor antagonists α-helical CRH 9-41 or astressin. (A) αT3-1 cells were treated with DMEM/IBMX containing vehicle, 10 μM α-helical CRH 9-41 (9-41), 100 nM CRH, 100 nM UCN, or 9-41 plus CRH or UCN for 3 min. Intracellular cAMP levels after 9-41, CRH, or UCN treatments were significantly increased from vehicle-treated levels (VEH; *significance from VEH, P < 0.05). In addition, treatments with 9-41 in the presence of CRH or UCN blocked the CRH- and UCN-mediated increases in intracellular cAMP (*significantly different from CRH or UCN treatments alone, P < 0.05). (B) αT3-1 cells were treated as above except that astressin (AST, 1 μM) was used alone or in combination with 100 nM CRH or UCN. These results also show significant inductions in cAMP levels with CRH and UCN and significant repressions of CRH- or UCN-mediated increases in cAMP by the addition of astressin. * and # are used as in (A).
weak intrinsic agonist activity (Baldwin et al. 1991, Hauger et al. 2006). A second non-selective CRH receptor antagonist, AST (Fig. 4B), also showed complete suppression of the CRH- and UCN-mediated increases in cAMP, with no significant effect of AST alone. Together, these studies clearly demonstrate that CRH and UCN mediate significant increases in the intracellular cAMP levels that can be effectively inhibited by the CRH receptor antagonists that block both CRHR1 and CRHR2 signaling.

Contributions of CRHR2 to the cAMP signaling in αT3-1 cells

To determine the contribution of CRHR2 to the overall cAMP increases in αT3-1 cells in response to CRH ligands, we stimulated the cells with various doses of UCN2 and UCN3, CRHR2-specific ligands (Jahn et al. 2004). The EC50 values for cAMP stimulation for UCN2 and UCN3 were 20.3 nM ± 9.7 (n = 3) and 32.5 nM ± 8.2 (n = 3), not significantly different from each other or the EC50 value of UCN (21.2 ± 5.2 nM, n = 7). At maximal doses of UCN2 and UCN3 (100 nM), we observed increases in cAMP levels that reached 60.0 ± 7.6% (n = 6) and 54.3 ± 6.0% (n = 13) of the levels obtained with UCN or CRH (90.9 ± 11.0% relative to UCN; Fig. 5A), demonstrating that both CRHR1 and CRHR2 can contribute to the cAMP increases in αT3-1 cells.

To further confirm the contribution of CRHR2 to the UCN-mediated increases in cAMP, we utilized a selective CRHR2 antagonist, antisauvagine (Ruhmann et al. 1998, Brauns et al. 2002). This peptide has a 100- to 400-fold greater selectivity for CRHR2 than CRHR1. The cells were pretreated with antisauvagine for 15 min before the addition of UCN or the CRHR2-specific agonist, UCN 3. As shown in Fig. 5B, the cAMP levels after antisauvagine treatment alone did not significantly differ from the vehicle. However, antisauvagine completely blocked the UCN3-mediated increase in cAMP, while only partially blocking (75% repression) the UCN-mediated cAMP increases, consistent with both CRHR1 and CRHR2 contributing to the UCN-mediated cAMP increases.

UCN increases α-luciferase transcriptional activity

While LHB and FSHB are not produced in αT3-1 cells, the glycoprotein hormone α-subunit is actively transcribed and translated in these cells and its expression is highly regulated by GNRH1, gonadal steroids, and a variety of peptides including pituitary adenyl cyclase activating polypeptide (PACAP) and endothelin 1, working through numerous intracellular signaling pathways (reviewed in McArdle & Cousin (1996) and Evans (1999)). PACAP has been shown to increase the intracellular cAMP levels in αT3-1 cells, resulting in increased transcriptional activity and steady-state levels of α-subunit mRNA (Schomerus et al. 1994, Tsuji et al. 1995, Attardi & Winters 1998, Burrin et al. 1998). As the cAMP levels are also rapidly increased by CRH or UCN in these cells, we utilized a mouse α-subunit promoter–luciferase reporter construct (α-luciferase) in transfection studies to assess the increased transcriptional activity of the α-subunit promoter in αT3-1 cells after treatment with UCN. As shown in Fig. 6, UCN significantly increased α-luciferase activity in a dose-dependent manner from 30 to 300 nM, reaching levels that were not significantly different from those induced by forskolin, a direct activator of adenylyl cyclase. As the mouse α-subunit promoter is known to contain cAMP response elements and has previously been shown to be activated by increased cAMP/PKA activation

Figure 5 Functional role of CRHR2 in cAMP signaling in αT3-1 cells. (A) αT3-1 cells were treated with vehicle, CRH, UCN, UCN2, or UCN3 (100 nM) for 3 min. Intracellular cAMP levels were determined and the increase in cAMP levels under each treatment condition (from vehicle) was normalized to that observed with UCN (set to 100%). UCN2 and UCN3 showed significantly lower elevations in cAMP, showing only 50–60% of the increases obtained with UCN or CRH (∗significantly different from UCN, P < 0.05), suggesting that CRHR2 contributes ∼50% to the cAMP increases observed after stimulation with UCN. (B) αT3-1 cells were pretreated with antisauvagine (AS, 1 μM) or vehicle for 15 min followed by a 3-minute treatment with UCN or UCN3 (100 nM) in the presence or absence of antisauvagine. Intracellular cAMP levels after UCN treatments were significantly increased from vehicle-treated levels (VEH; ∗significantly different from VEH, P < 0.05), with UCN-mediated increases being significantly greater than UCN3-mediated increases. There was no significant difference in the intracellular cAMP levels between VEH and AS treatments. Treatment with AS in the presence of UCN3 completely blocked the UCN3-mediated increases (∗∗significantly different from UCN3, P < 0.05), resulting in cAMP levels not significantly different from VEH or AS. Treatment with AS in the presence of UCN significantly reduced cAMP levels from UCN (∗∗significantly different from UCN, P < 0.05), but cAMP levels remained significantly greater than VEH, AS/VEH, or AS/UCN3 levels, suggesting that activated CRHR1 was responsible for the remaining cAMP increase.
In the rodent, Cshr1 mRNA has been localized primarily in the brain and intermediate and anterior lobes of the pituitary (Potter et al. 1994, Van Pett et al. 2000). While Cshr1 mRNA had previously been detected in a subset of rat corticotropes (Potter et al. 1994), recent studies from our laboratory have also demonstrated Cshr1 mRNA in a subset of cells expressing ACTH, prolactin, or LHB transcripts in the mouse anterior pituitary (Westphal et al. 2009), consistent with the expression of CRHR1 in the mouse gonadotrope-like αT3-1 cell line. CRHR2 expression in the rodent is quite distinct from CRHR1, with a more restricted pattern in the brain but numerous sites of expression in the periphery (Chalmers et al. 1996, Van Pett et al. 2000). While the two rodent isoforms of CRHR2, CRHR2α and CRHR2β, show comparable pharmacological properties (Hauger et al. 2006), they differ significantly in their tissue-specific expression. In situ hybridization studies using probes from the common region of CRHR2 have demonstrated C Chr2 mRNA expression in the posterior pituitary, with a weak but clearly detectable signal in the anterior pituitary (Van Pett et al. 2000), most likely in gonadotropes (Kageyama et al. 2003). CRHR2α mRNA has also been detected in anterior pituitary by ribonuclease protection assay (Kageyama et al. 2003). Consistent with these results, we have detected CRHR2α mRNA, but not CRHR2β, in αT3-1 cells by RT-PCR. Together, these results suggest that a population of gonadotropes may express both CRHR1 and CRHR2α at certain times in development or in response to specific hormonal signals.

The expression of CRHR1 and CRHR2α on αT3-1 cells that also express GNRH1 receptors is quite interesting in the light of the recent studies demonstrating the significant population of anterior pituitary cells in rat and mouse that exhibit multiple hypothalamic releasing hormone (HRH) receptors (multi-responsive cells; Nunez et al. 2003, Villalobos et al. 2004). Recent studies have suggested that 38% of female mouse anterior pituitary cells express multiple HRH receptors, with almost 50% of LHB-positive cells being multi-responsive (Nunez et al. 2003). Our results are consistent with these studies and suggest that anterior pituitary cells are more multifunctional than previously thought, with great potential for crosstalk between HRH and pituitary hormonal release. Interestingly, CRH has recently been shown to induce thyrotropin release from the amphibian pituitary gland via CRHR2 signaling (Okada et al. 2007).

In response to treatment with CRH or UCN, the αT3-1 cells show a very rapid increase in the intracellular cAMP levels, demonstrating the positive coupling of the CRH receptors to Gs, and adenyl cyclase after ligand stimulation. The rapid rise in the intracellular cAMP levels in αT3-1 cells in response to CRH or UCN with a peak at 2–5 min followed by a rapid decline is similar to the results seen with murine atrial cardiomyocyte tumor cells, AT-1 cells, which express endogenous CRHR2β mRNA (Heldwein et al. 1996). The rapid decline in the cAMP levels even in the

![Figure 6](https://example.com/figure6.png)
presence of IBMX is quite interesting, and it may suggest that one or both types of CRH receptors on αT3-1 cells are desensitized quickly following exposure to ligand. This theory is supported by the reports of rapid agonist-induced CRHR1 desensitization and internalization (Roseboom et al. 2001, Teli et al. 2005). Alternatively, the dose of IBMX used in these studies may not be sufficient to inhibit all phosphodiesterase activity in these cells.

The responses to CRH and the urocortins in the αT3-1 cells were dose dependent and specific for CRH receptors, as the presence of non-selective CRH receptor antagonists, α-helical CRH 9–41 or AST, completely inhibited the intracellular cAMP increases. Similar peak cAMP values were observed with CRH or UCN, ligands that activate both CRHR1 and CRHR2α. By contrast, peak cAMP values with UCN2 and UCN3 stimulation reached levels only 50–60% of UCN- or CRH-stimulated levels, consistent with their CRHR2 selectivity. Similarly, the significant, but incomplete, inhibition of UCN-mediated increases in cAMP production in αT3-1 cells with antisauvagine, the CRHR2-specific antagonist (100–400-fold greater binding to CRHR2), was consistent with the UCN-mediated activation of both CRHR1 and CRHR2α. The EC50 values for cAMP production in αT3-1 cells were not significantly different between CRH, UCN, UCN2, or UCN3, and ranged from 14 to 32 nM. Studies in cell lines that have been stably or transiently transfected with CRH receptors have shown EC50 values for CRHR1 of 1–3 nM for both CRH and UCN and EC50 values for CRHR2 of 0.2–20 nM (Vaughan et al. 1995). Primary cultures or cultured cell lines expressing endogenous CRH receptors have shown higher EC50 values (Heldwein et al. 1996).

While stress-induced suppression of GNRH1 and LHB release is clearly dependent on central actions of CRH (Li et al. 2005, 2006), the finding that αT3-1 cells, a gonadotrope-like cell line, express CRH receptors suggests an additional and potential direct role for CRH or urocortins on gonadotrope function, consistent with the recent studies that have identified Crhr1 or Crhr2 mRNA in rat or mouse gonadotropes (Kageyama et al. 2003, Westphal et al. 2009). Our studies here extend the previous results to demonstrate that these CRH receptors are functional, increasing the intracellular cAMP levels resulting in transcriptional activation of cAMP-responsive genes including the glycoprotein hormone α-subunit. PACAP has also been shown to increase cAMP levels in αT3-1 cells, resulting in increased α-subunit expression (Schomerus et al. 1994, Tsuji et al. 1995, Attardi & Winters 1998). Interestingly, while GNRH1 does not alter cAMP levels in αT3-1 cells, GNRH1 significantly reduces the PACAP-mediated increase in cAMP levels via the activation of the PKC signaling pathway (McArdle et al. 1994, McArdle & Counis 1996), emphasizing the importance of crosstalk between distinct intracellular signaling pathways in these gonadotrope-like cells. It is possible that GNRH1 may also modify the CRH-mediated increases in cAMP in these cells. Similarly, we have initiated preliminary studies of GNRH1 signaling and phospholipase C (PLC) activation in αT3-1 cells. While GNRH1 treatment dramatically increases total inositol phosphate levels via PLC activation, CRH treatment alone has no significant effect on inositol phosphate levels (unpublished data, A. Seasholtz). However, if CRH and GNRH1 are co-administered, CRH significantly decreases the GNRH1-mediated increases in inositol phosphates, showing another level of crosstalk between the PKA and PLC/PKC signaling pathways in these gonadotrope-like cells (unpublished data, A. Seasholtz). Functional interactions between the PKA and PLC/PKC systems have also been observed in the LBT2 gonadotrope-like cell line, with GNRH1 stimulating PACAP receptor phosphorylation by PKC (Lariviere et al. 2008). Hence, while αT3-1 cells represent only a model of gonadotrope function, these studies suggest that CRH receptor signaling on pituitary gonadotropes may contribute, along with other peptide and gonadal hormones, to the modulation of GNRH1 signaling at these cells and resultant gonadotropin synthesis and release.

Finally, it should also be noted that the CRH-binding protein (CRHBP) is highly expressed in rodent anterior pituitary (Speert et al. 2002). This secreted glycoprotein binds CRH and UCN with high affinity and is thought to act largely as an inhibitory protein, binding the ligands and decreasing CRH receptor activation (reviewed in Westphal & Seasholtz 2006)). CRHBP expression is positively regulated by estrogen, resulting in a sexually dimorphic pattern of expression with CRHBP detected in corticotropes in male mice, while it is detected in corticotropes, lactotropes, and gonadotropes in female mice (Speert et al. 2002). CRHBP is also expressed in αT3-1 cells where its expression is regulated by GNRH1 (Westphal & Seasholtz 2005). Hence, the actions of CRH and UCN on αT3-1 cells or gonadotropes in vivo may be highly regulated by the pituitary CRHBP.

In conclusion, we have demonstrated that αT3-1 cells express Crhr1 and CRHR2α mRNAs and that these CRH receptors are functionally coupled to the Gs signal transduction pathways. These receptors respond to CRH, UCN, UCN2, or UCN3 treatment with rapid, transient increases in intracellular cAMP levels, and CRH receptor antagonist data confirm the contributions of both CRHR1 and CRHR2 to the cAMP inductions. The activation of these receptors also increases the transcriptional activity of the glycoprotein hormone α-subunit promoter, a well-characterized cAMP-responsive promoter. Since αT3-1 cells serve as a model for gonadotrope cells, these data suggest a potential direct role for CRH or the other CRH-like ligands, UCN, UCN2, and UCN3, in the coordinated control of gonadotropin expression and secretion at the gonadotrope. Studies in primary mouse anterior pituitary cultures and in vivo will allow us to further examine the actions of CRH and urocortins (and the CRHBP) on both basal and stimulated pituitary hormone release, potentially revealing new roles for these ligands in pituitary function.


www.endocrinology-journals.org

Downloaded from Bioscientifica.com at 06/07/2022 09:41:33PM via free access
Declaration of interest

The authors have no conflict of interest to report.

Funding

The studies were supported by NIH grants DK54323 to R. C. T and DK42730 and DK57660 to A. F. S. We gratefully acknowledge the postdoctoral support of M. Ohman from the Academy of Finland (grant no. 52840) and the Finnish Medical Foundation.

Acknowledgements

We would like to thank Linda Harper Gates and Jyoti Kothavale for their assistance with αT3-1 studies. This work was presented in part at the 85th Annual Meeting of the Endocrine Society, Philadelphia, PA. While this manuscript was under revision, a separate manuscript from our laboratory was published, which documented CRH receptor expression in multiple anterior pituitary cell lines (including αT3-1 cells) and in murine corticotropes, lactotropes, and gonadotropes (Westphal et al. 2009).

References


Hillhouse E & Grammatopoulos D 2006 The molecular mechanisms underlying the regulation of the biological activity of CRH receptors: implications for physiology and pathophysiology. Endocrine Reviews 27 260–286.


Hu S & Hsu C 2001 Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nature Medicine 7 605–611.


Lovenberg TW, Chalmers DT, Liu C & DeSouza EB 1995α CRF2a and CRF2b receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 136 4139–4142.


McArkle CA & Cousin R 1996 GnRH and PACAP action in gonadotropes
cross-talk between phosphoinositidase C and adenylyl cyclase mediated
signaling pathways. Trends in Endocrinology and Metabolism 7 168–175.
McArkle CA, Poch A, Schomerus E & Kratzmeier M 1994 Pituitary adenylyl
cyclase-activating polypeptide effects in pituitary cells: modulation by
gonadotropin-releasing hormone in alpha T3-1 cells. Endocrinology 134
2599–2605.
Nunez L, Villalobos C, Senovilla L & Garcia-Sancho J 2003 Multifunctional
cells of mouse anterior pituitary reveal a striking sexual dimorphism.
2007 Involvement of the corticotropin-releasing factor (CRF) type 2
receptor in CRF-induced thyrotropin release by the amphibian pituitary
Owens MJ & Nemecoff CB 1991 Physiology and pharmacology of
Van Pett K, Viss V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS,
Perrin M, Vale WW & Sawchenko PE 2000 Distribution of mRNAs
encoding CRF receptors in brain and pituitary of rat and mouse. Journal of
Comparative Neurology 428 191–212.
& Vale W. 1994 Distribution of corticotropin-releasing factor receptor
mRNA expression in the rat brain and pituitary. PNAS 91 8777–8781.
Reyes TM, Lewis K, Perrin M, Kunitake KS, Vaughan J, Arias CA,
member of the corticotropin-releasing factor (CRF) neuropeptide family
that is selectively bound by type 2 CRF receptors. PNAS 98 2843–2848.
Rivest S & Rivier C 1995 The role of CRF and interleukin-1 in the
regulation of neurons controlling reproductive functions. Endocrine Reviews
16 177–200.
Rivier C & Vale W 1984 Influence of corticotropin-releasing factor on
reproductive functions in the rat. Endocrinology 114 914–919.
Roseboom PH, Urban CM & Kalin NH 2001 Persistent corticotropin-
releasing factor(1) receptor desensitization and downregulation in the
human neuroblastoma cell line IMR-32. Brain Research. Molecular Brain
Research 92 115–127.
Ruhmann A, Bonk I, Lin CR, Rosenfeld MG & Spiess J 1998 Structural
requirements for peptidic antagonists of the corticotropin-releasing factor
receptor (CRFR): development of CRFR2b-selective antisauvagine-30.
PNAS 95 15264–15269.
Schoderbek WE, Kim KE, Ridgway EC, Mellon PL & Maurer RA 1992
Analysis of DNA sequences required for pituitary-specific expression of the
glycoprotein hormone alpha-subunit gene. Molecular Endocrinology 6
893–903.
Schomerus E, Poch A, Bunting R, Mason WT & McArkle CA 1994 Effects of
pituitary adenylyl cyclase-activating polypeptide in the pituitary: activation
of two signal transduction pathways in the gonadotrope-derived alpha T3-1
cell line. Endocrinology 134 315–323.
Speer DB, SJ MC & Seasholtz AF 2002 Sexually dimorphic expression of
corticotropin-releasing hormone-binding protein in the mouse pituitary.
Endocrinology 143 4730–4741.
Teli T, Markovic D, Levine MA, Hillhouse EW & Grammatopoulos DK 2005
Regulation of corticotropin-releasing hormone receptor type 1 alpha
signaling: structural determinants for G protein-coupled receptor kinase-
mediated phosphorylation and agonist-mediated desensitization. Molecular
Endocrinology 19 474–490.
Tsujii T, Attardi B & Winters SJ 1995 Regulation of alpha-subunit mRNA
transcripts by pituitary adenylyl cyclase-activating polypeptide (PACAP) in
pituitary cell cultures and alpha T3-1 cells. Molecular and Cellular
Endocrinology 113 123–130.
R, Turnbull AV, Lovejoy D, Rivier C et al. 1995 Urocortin, a mammalian
neuropeptide related to fish urotensin I and to corticotropin-releasing
Villalobos C, Nunez L & Garcia-Sancho J 2004 Anterior pituitary thyrotropes
are multifunctional cells. American Journal of Physiology. Endocrinology and
Metabolism 287 E1166–E1170.
Westphal NJ & Seasholtz AF 2005 Gonadotropin-releasing hormone (GnRH)
positively regulates corticotropin-releasing hormone-binding protein
expression via multiple intracellular signaling pathways and a multipartite
GnRH response element in alpha T3-1 cells. Molecular Endocrinology 19
2780–2797.
Westphal NJ & Seasholtz AF 2006 CRH-BP: the regulation and function of
a phylogenetically conserved binding protein. Frontiers in Bioscience 11
1878–1891.
Westphal NJ, Evans RT & Seasholtz AF 2009 Novel expression of type 1
CRH receptor in multiple endocrine cell types in the murine anterior
Windle JJ, Weiner RJ & Mellon PL 1990 Cell lines of the pituitary
gonadotrope lineage derived by targeted oncogenesis in transgenic mice.
Molecular Endocrinology 4 597–603.

Received in final form 22 October 2008
Accepted 11 November 2008
Made available online as an Accepted Preprint 13 November 2008